ClinicalTrials.gg
RecruitingNCT07174310PARAISOUpdated Nov 5, 2026

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

A Phase 3 interventional study of Prasinezumab and Placebo in Parkinson's Disease, sponsored by Hoffmann-La Roche. Recruiting at 192 sites in 17 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Nov 5, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
18th of 1,256
900 · median 36
Started
2025
with 77 others
Phase 3
126 of 1,649
2 open now
Primary completion
2029-06
later than 320 of 383 live
Registered
1,550th of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 18th largest by planned enrollment of the 1,256 interventional ones that give a count, is one of 78 that started in 2025, is one of 126 in phase 3, reaches primary completion later than 320 of the 383 other live ones, and was the 1,550th registered.

Parkinson Disease

4,580 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight within 40-110 kilograms (kg) (88-242 pounds [lbs]) and a within the range 18-34 kg/m2
  • Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria
  • Has received monotherapy treatment
  • An MDS-UPDRS Part IV score of 0 at screening and prior to randomization
  • Hoehn and Yahr (H\&Y) Stage 1 or 2 off medication at screening and prior to randomization
  • Agreement to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which is required
  • Medical history indicating a parkinsonian syndrome other than idiopathic PD
  • Diagnosis of a significant neurologic disease other than PD
  • Chronic uncontrolled hypertension
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Prasinezumab

    Participants will receive Prasinezumab as an IV infusion in the double blind treatment period. Upon completion, eligible participants will enter into the Open Label Extension (OLE) phase.

    Drug: Prasinezumab

  • Experimental
    Placebo

    Participants will receive placebo as an IV Infusion.

    Drug: Placebo

Interventions

  • Participants will receive Prasinezumab as an IV Infusion as per the schedule mentioned in the protocol.

  • DrugPlacebo

    Participants will receive Placebo as an IV Infusion per the schedule mentioned in the protocol

06

What researchers measure

Primary outcomes

  1. Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score

    Time frame: Up to at least Week 104

Secondary outcomes

  1. Change From Baseline in Motor Function as Measured by the MDS-UPDRS Part III off Medication Score

    Time frame: Baseline, Week 104

  2. Time to Worsening of Participants Motor Function as Reported by the Participant in the Presence of a Confirmed Motor Progression Event

    Time frame: Up to at least Week 104

  3. Time to Meaningful Worsening in Clinician Global Impression of Change (CGI-C), Overall Disease Subscale

    Time frame: Up to at least Week 104

  4. Time to increase in Levodopa Equivalent Daily Dose (LEDD)

    Time frame: Up to at least Week 104

  5. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: From Baseline up to 70 days after the final study dose (up to at least Week 104)

  6. Percentage of Participants With Adverse Events of Special Interest (AESI)

    Time frame: From Baseline up to 70 days after the final study dose (up to at least Week 104)

  7. Percentage of Participants With Infusion Related Reactions (IRRs)

    Time frame: From Baseline up to 70 days after the final study dose (up to at least Week 104)

  8. Percentage of Participants With Suicidal Ideation, as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: From Baseline up to 70 days after the final study dose (up to at least Week 104)

  9. Serum Concentration of Prasinezumab

    Time frame: Predose and postdose at Baseline, Week 1, 4, 12, 24, 36, 52, 76, and after week 76 every 12 weeks thereafter until end of study (up to at least Week 104)

  10. Percentage of Participants With Anti-drug Antibodies (ADAs) Against Prasinezumab at Baseline

    Time frame: At Baseline

  11. Percentage of Participants With ADAs Against Prasinezumab During the Study

    Time frame: From Baseline up to 70 days after the final study dose (up to at least Week 104)

07

Study locations

183 of 192 sites recruiting

Showing the first 100 of 192 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Nikolcheva T, Pagano G, Anzures-Cabrera J, Trundell D, Kustermann T, Simuni T, Marek K, Pavese N, Seppi K, Stocchi F, Postuma RB, Pross N, Monnet A, Respondek G, Schlegel V, Boak L, Rutten-Jacobs L, Kerchner GA, Brundin P, Svoboda H, Bonni A; PADOVA Investigators; Prasinezumab Study Group. Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. Lancet. 2026 May 30;407(10544):2227-2240. doi: 10.1016/S0140-6736(26)00865-2. PubMed 42208564 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2029, 43 months after the start.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's planned 43 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 15, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites changed recruiting status (7 now active, not recruiting)
Show 7 sites
  • Ninewells Hospital, Dundee- Scotland · Dundee, United KingdomRecruiting→Active, not recruiting
  • Royal Devon and Exeter Hospital (Wonford) · Exeter, United KingdomRecruiting→Active, not recruiting
  • Royal London Hospital · London, United KingdomRecruiting→Active, not recruiting
  • Charing Cross Hospital · London, United KingdomRecruiting→Active, not recruiting
  • Campus for Ageing and Vitality · Newcastle, United KingdomRecruiting→Active, not recruiting
  • Oxford University Hospitals NHS Foundation Trust · Oxford, United KingdomRecruiting→Active, not recruiting
  • Plymouth Hospitals NHS Trust - Derriford Hospital · Plymouth,Devon, United KingdomRecruiting→Active, not recruiting
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    7 sites changed recruiting status (7 now active, not recruiting)
    Show 7 sites
    • Ninewells Hospital, Dundee- Scotland · Dundee, United KingdomRecruiting→Active, not recruiting
    • Royal Devon and Exeter Hospital (Wonford) · Exeter, United KingdomRecruiting→Active, not recruiting
    • Royal London Hospital · London, United KingdomRecruiting→Active, not recruiting
    • Charing Cross Hospital · London, United KingdomRecruiting→Active, not recruiting
    • Campus for Ageing and Vitality · Newcastle, United KingdomRecruiting→Active, not recruiting
    • Oxford University Hospitals NHS Foundation Trust · Oxford, United KingdomRecruiting→Active, not recruiting
    • Plymouth Hospitals NHS Trust - Derriford Hospital · Plymouth,Devon, United KingdomRecruiting→Active, not recruiting
    + 1 other change: verification date
  2. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07174310
Lead sponsor
Hoffmann-La Roche
Collaborators
Prothena Biosciences Limited
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Nov 24, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: BN44715 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prasinezumab

Start the discussion